Clinical and Translational Science Institute

Centers

1-1-2018

Bacteria antibiotic resistance: New challenges and opportunities
for implant-associated orthopedic infections
Bingyun Li
West Virginia University

Thomas J. Webster
Northeastern University

Follow this and additional works at: https://researchrepository.wvu.edu/ctsi
Part of the Medicine and Health Sciences Commons

Digital Commons Citation
Li, Bingyun and Webster, Thomas J., "Bacteria antibiotic resistance: New challenges and opportunities for
implant-associated orthopedic infections" (2018). Clinical and Translational Science Institute. 739.
https://researchrepository.wvu.edu/ctsi/739

This Article is brought to you for free and open access by the Centers at The Research Repository @ WVU. It has
been accepted for inclusion in Clinical and Translational Science Institute by an authorized administrator of The
Research Repository @ WVU. For more information, please contact ian.harmon@mail.wvu.edu.

HHS Public Access
Author manuscript
Author Manuscript

J Orthop Res. Author manuscript; available in PMC 2018 March 06.
Published in final edited form as:
J Orthop Res. 2018 January ; 36(1): 22–32. doi:10.1002/jor.23656.

Bacteria Antibiotic Resistance: New Challenges and
Opportunities for Implant-Associated Orthopaedic Infections
Bingyun Li1,2,* and Thomas J. Webster3,4,*
1Department

of Orthopaedics, School of Medicine, West Virginia University, Morgantown, WV

26506, USA

Author Manuscript

2Mary

Babb Randolph Cancer Center, Morgantown, WV 26506, USA

3Department

of Chemical Engineering, Northeastern University, Boston, MA 02115, USA

4Center

of Excellence for Advanced Materials Research, King Abdulaziz University, Jeddah,
Saudi Arabia

Abstract
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There has been a dramatic increase in the emergence of antibiotic resistant bacterial strains, which
has made antibiotic choices for infection control increasingly limited and more expensive. In the
U.S. alone, antibiotic resistant bacteria cause at least 2 million infections and 23,000 deaths a year
resulting in a $55–70 billion per year economic impact. Antibiotics are critical to the success of
surgical procedures including orthopaedic prosthetic surgeries, and antibiotic resistance is
occurring in nearly all bacteria that infect people, including the most common bacteria that cause
orthopaedic infections, such as Staphylococcus aureus (S. aureus). Most clinical cases of
orthopaedic surgeries have shown that patients infected with antibiotic resistant bacteria, such as
methicillin resistant S. aureus (MRSA), are associated with increased morbidity and mortality.
This paper reviews the severity of antibiotic resistance at the global scale, the consequences of
antibiotic resistance, and the pathways bacteria used to develop antibiotic resistance. It highlights
the opportunities and challenges in limiting antibiotic resistance through approaches like the
development of novel, non-drug approaches to reduce bacteria functions related to orthopaedic
implant-associated infections.
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1. Antibiotic resistance – a serious global problem
Antibiotics have revolutionized medicine, including improving orthopaedic surgical and
implant outcomes, in many respects and have transformed human health and well-being for
the better. Before the use of antibiotics, the fatality rate for Staphylococcus aureus (S.
aureus) bacteremia was high and most wound infections were treated by amputation; for
instance, ~70% of amputations in World War I were result of wound infections.1 The
introduction of antibiotics has dramatically improved the fate of infected patients and has
changed the way various diseases and surgical procedures are treated. The ability of
antibiotics to treat and cure infection has dramatically reduced the number of incidences of
infection, significantly improving the quality of life for numerous patients, reducing
childhood mortality, increasing life expectancy, and saving numerous lives.
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Antibiotics were first studied in the late 1800s and it was in early 1900s that penicillin was
discovered. The value of using penicillin during and after orthopaedic surgeries was first
highly appreciated during World War II when treating casualties from the War. The success
of penicillin was followed by the development of a variety of new antibiotics. Currently,
cephalosporins (e.g., cefazolin, cefalotin), aminoglycosides (e.g., gentamicin, tobramycin,
amikacin), glycopeptide antibiotics (e.g., vancomycin, teicoplanin), and quinolones (e.g.,
ciprofloxacin, ofloxacin) have been extensively used in orthopaedic surgeries to prevent or
treat infections.
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Unfortunately, the discovery and increasingly widespread use (especially the misuse) of
antibiotics have led to the rapid appearance of antibiotic resistant strains today; more and
more infections are caused by microorganisms that fail to respond to conventional
treatments. Meanwhile, the discovery and development of antibiotics have been declining
rapidly over the past several decades; for instance, 16, 14, 10, and 7 new antibiotics were
approved during 1983–1987, 1988–1992, 1993–1997, and 1998–2002, respectively, while
only 5 and 2 were approved during 2003–2007 and 2008–2012, respectively.2 This decline
was due to decreasing antibiotic research and development in major pharmaceutical
companies;2 investment in new antibiotic development has been hampered by the uncertain
lifecycles (associated with antibiotic resistance development) of new antibiotic drugs and
government regulations affecting the pace of translational exploitation.3
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The approximate timeline for the introduction of multiple major antibiotics and the
subsequent emergence of clinically significant bacteria antibiotic resistance is shown in Fig.
1.4 Following the introduction of sulfonamides and penicillin around 1937 and 1940,
resistance to sulfonamides and penicillin were reported within a few years (around 1945).
Resistance to tetracycline, streptomycin, and chloramphenicol was found in the 1950s.
Methicillin was introduced in 1959 and methicillin resistant S. aureus (MRSA) was
identified in 1961. MRSA has since become widespread in hospitals and, relatively recently,
in numerous communities worldwide leading to the consideration of antibiotic resistance as
a real threat to human health. Linezolid and daptomycin were introduced in the 2000s and
their resistance was reported within five years. In fact, a report was given to the United
Nations in 2016 concerning the significant consequences of antibiotic resistance to human

J Orthop Res. Author manuscript; available in PMC 2018 March 06.

Li and Webster

Page 3

Author Manuscript

health; this report represents only the second time in the history of the United Nations that
threats to human health have been presented.

Author Manuscript

Currently, the most notorious antibiotic resistant bacteria is S. aureus, and antibiotic resistant
microorganisms including Enterococcus faecium, S. aureus, Klebsiella pneumoniae,
Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species have been
identified as the so-called “ESKAPE” microorganisms which have caused significant
morbidity and mortality.5 In the U.S., the Centers for Disease Control and Prevention (CDC)
has also classified multidrug resistant (MDR) microorganisms into three different levels (i.e.,
threat levels of urgent, serious, and concerning).6 Among these MDR microorganisms, many
of them have been reported in orthopaedic implant-associated infections including MRSA,
vancomycin-resistant S. aureus (VRSA), multidrug-resistant Acinetobacter, extended
spectrum β-lactamase producing enterobacteriaceae (ESBLs), and multidrug-resistant
Pseudomonas aeruginosa. Their resistance has a broad effect on treating and preventing
infections (Table 1).7 The consequences of antibiotic resistance are very serious, and could
present a significant impact on morbidity and mortality and lead to financial burdens for
patients and public health systems, as described below:
Antibiotic resistance likely compromises the safety and efficacy of surgical
procedures like implantation and transplantation that require the protection of
antibiotics. It is estimated that between 38.7% and 50.9% of microorganisms
causing surgical site infections are resistant to standard prophylactic antibiotics
in the U.S.7

•

Antibiotic resistance has a direct effect on treating infections. Patients (not
orthopaedic specific) with infections caused by MDR microorganisms are
generally at increased risk of worse clinical outcomes and death, and consume
more health-care resources compared with similar infections caused by antibiotic
susceptible strains.8 Approximately a two-fold increase in morbidity, mortality,
and cost for patients with resistant versus susceptible infections has been
reported in patients (not orthopaedic specific) who had clinical cultures positive
for Enterobacter species.9 A two-fold higher risk of death was attributed to
infections caused by carbapenem-resistant K. pneumoniae compared to
infections caused by carbapenem-susceptible strains in adult patients with K.
pneumoniae bacteremia.10 Meanwhile, hospitals spend, on average, an additional
$10,000–40,000 to treat a patient infected by resistant bacteria versus susceptible
strains.11 According to the CDC, in the U.S. alone, antibiotic resistant bacteria
cause at least 2 million infections, 23,000 deaths a year,6 and $55–70 billion per
year in economic impact.12,13 In Europe, approximately 25,000 people die
annually due to MDR bacterial infections, along with a 1.5 billion per year cost
in the economy.14,15

•

Antibiotic resistance may have negative effects on domesticated animals such as
pets and farm animals.16
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•
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2. Molecular mechanisms of antibiotic resistance
Antibiotic resistance is defined as the ability of microorganisms to resist the effects of drugs
(e.g., antibiotics) – that is, the germs are not killed and their growth is not stopped.17
Resistance to a specific antibiotic is relative to the microorganisms to be tested and their
previous antibiotic exposures. The molecular mechanisms of antibiotic resistance have been
extensively reviewed.14,18 There are two distinct types of antibiotic resistance: intrinsic and
acquired. Microorganisms can be intrinsically resistant to certain antibiotics as a result of
inherent structural or functional characteristics (Fig. 2A).14 For instance, a particular
antibiotic may be structurally unable to penetrate the outer membrane of certain
microorganisms or the antibiotic entering the membrane is removed by efflux pumps.
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Meanwhile, microorganisms may have acquired resistance that can be obtained via
chromosomal mutations or, more commonly, by acquiring an antibiotic resistance gene from
another bacterium via mobile plasmids or transposons (so called horizontal gene transfer).19
According to Riedl et al., currently, there are five main targets (i.e., cell wall synthesis,
protein synthesis, RNA polymerase and DNA gyrase, folate mechanism, and membrane
structure) for antibiotics, and antibiotic resistance can essentially be acquired through four
different pathways (i.e., transformation, transduction, conjugation, and mutation) and
expressed by four different mechanisms (i.e., prevention of cell penetration, expulsion via
efflux pumps, inactivating proteins, and modification of the target) (Fig. 2B).19 For instance,
MRSA is resistant to numerous penicillin-like β-lactam antibiotics primarily due to its
expression of the mecA gene which encodes the low affinity penicillin binding protein PBP
2a.20 The Antibiotic Resistance Genes Database currently lists the existence of more than
23,000 potential resistance genes of about 380 different types from available bacterial
genome sequences.21 Fortunately, the number of functional resistance genes is much
smaller.
Biofilm formation is also believed to be one key means of antibiotic resistance in
orthopaedic implant-associated infections. Bacterial biofilms are inherently resistant to
antibiotics22 because (i) certain antibiotics fail to penetrate the full depth of the biofilm, (ii)
some cells within biofilms are slow-growing or nongrowing probably as a result of nutrient
limitation, and (iii) some cells within biofilms may adopt a distinct and protected biofilm
phenotype. For instance, biofilm forming S. epidermidis strains (126 out of 342), compared
to those non-producing isolates, presented a significantly higher prevalence of resistance to
ciprofloxacin and sulfamethoxazole as well as the four aminoglycosides.23

Author Manuscript

A variety of factors including human activities may influence the presence of antibiotic
resistance and antibiotic resistance genes are omnipresent in natural environments.
Numerous types of anthropogenic activity (such as antibiotic use in agriculture and
antibiotic presence in waste disposal) have created major environmental reservoirs for
antibiotic resistance genes.24 Animals, wind, water, etc., may disseminate antibiotic
resistance genes throughout the environment.25 As a result, wastewater treatment plants have
been found to be rich in antibiotic resistance genes and resistant microorganisms,26 and
bacteriophages (viruses that infect bacteria), found in wastewater, are reservoirs of antibiotic
resistance genes.27

J Orthop Res. Author manuscript; available in PMC 2018 March 06.

Li and Webster

Page 5

Author Manuscript

It is noteworthy to mention that antibiotic resistance mechanisms have existed for a long
time. Antibiotic resistance genes and resistance-encoding integrons have been found in the
gut flora of people who are not exposed to antibiotics and who have been apparently isolated
from modern civilization.28,29 Furthermore, genes encoding resistance to β-lactam,
tetracycline, and glycopeptide antibiotics have been identified from the 30,000-year-old
DNA found in Beringian permafrost sediments.30

3. Antibiotic resistance profiles in orthopaedic implant-associated
infections
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Orthopaedic implant-associated infections are often treated with multiple surgical
procedures along with systemic and/or local antibiotic treatment. It is well known that
Staphylococci (especially S. aureus and S. epidermidis) are the most common causative
microorganisms involved in orthopaedic implant-associated infections. S. aureus has long
been recognized as exhibiting high levels of antibiotic resistance, while numerous other
microorganisms have been observed to exhibit increasing antibiotic resistance in the recent
years, including S. epidermidis23,31 and a number of less frequently seen Staphylococcal
species.32,33
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Numerous clinical studies have been reported about orthopaedic implant-associated
infections, along with increasing clinical studies focusing on antibiotic resistance and its
prevalence in orthopaedic implant-associated infections.32–38 In primary and revision
periprosthetic joint infections (PJIs), the most common infecting organisms were S. aureus
and coagulase-negative Staphylococci (CNS),34–36 and most strains were resistant to at least
one antibiotic (Table 2).32–37 Alarmingly, in some cases,36 CNS resistance to both
methicillin and gentamicin seems to be much higher than S. aureus and has been increasing,
which is a concern for future antibiotic prophylaxis. Antibiotic resistant Staphylococci were
also found to present in orthopaedic patients with loosened or failed hip prostheses even
without clinical manifestations of infection.37 The role of Staphylococci and their antibiotic
resistance prevalence may have been underestimated in previously considered “aseptic”
implant loosening failures.37 In addition, compared to isolates that were not associated with
orthopaedic implants, S. aureus strains isolated from orthopaedic implant-associated
infections were significantly more frequently resistant to ciprofloxacin and four
aminoglycosides (i.e., amikacin, gentamicin, netilmicin, and tobramycin).38
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Besides S. aureus and S. epidermidis, some less frequently seen species like S. hominis, S.
haemolyticus, S. capitis, S. warneri, S. cohnii, Escherichia coli (E. coli), and Klebsiella
pneumoniae were observed and were often found to be antibiotic resistant.32,33 These
usually less observed species, most of which have been thought to play a commensal role,
may potentially become pathogenic, especially in immunocompromised patients including
patients with orthopaedic implants. In view of their differences in prevalence and antibiotic
resistance, we would suggest that these less observed species also be monitored for their
prevalence, acquisition of antibiotic resistance, virulence, and pathogenic properties, and
may need to be treated individually.
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Meanwhile, older infected patients, who frequent present with compromised health, may
also have different antibiotic resistance profiles compared to younger patients. In a study of
163 patients with orthopaedic implant-associated infections, the Staphylococci found in the
older patients (age 60 and older) were more frequently methicillin resistant or MDR
compared to those associated with infections in younger patients.39 For instance, S.
epidermidis strains resistant to methicillin had a significantly higher prevalence in older
patients than in younger patients (91% vs. 66%, p = 0.006), and the corresponding MDR
prevalence was significantly higher in older patients as well (94% vs. 72%, p = 0.011).39
The observed compromised health status and poor bone quality in older infected patients
might have contributed to their higher antibiotic resistance prevalence compared to younger
patients.

4. Antibiotic resistance linked to less optimal clinical outcomes in
Author Manuscript

orthopaedic implant-associated infections
S. aureus is one of the most common causes of orthopaedic implant-associated infections,
with both methicillin-susceptible and -resistant strains. The incidence of MRSA and other
antibiotic resistance has increasingly been reported worldwide over the past decade. One
question has been raised but has not been clearly answered: Does antibiotic resistance
influence the clinical outcome of orthopaedic associated infections?
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Quite a few case studies have shown that antibiotic resistant bacteria have contributed to
worse clinical outcomes compared to those infected by antibiotic susceptible bacteria (Table
3).40–45 It was found that patients infected with MRSA had significantly longer hospital
stays,40 were at a significantly higher risk of treatment failure,40,41 had significantly more
surgical procedures,42,45 had significantly more co-morbidities,45 had significantly poorer
clinical outcomes,41 and had significantly lower satisfactory outcomes42 compared to those
infected with methicillin susceptible S. aureus or MSSA. Similar tends were reported in
infected children (less than 18 years old). Children with bone and joint infections infected
with MRSA had a significantly longer duration of febrile days and hospital stays43,44 and
antibiotic treatment44 compared to those infected with MSSA.

Author Manuscript

However, there are a few studies, likely underpowered, showing higher but not significantly
different morbidity or mortality rates between infections caused by antibiotic resistant and
susceptible microorganisms in orthopaedic implant-associated infections. In a recent large
multicenter study during 2003–2010, 342 PJI patients were identified with S. aureus, and
similar failure rates were observed for MRSA and MSSA (46 vs. 44%).46 Interestingly,
during antibiotic treatment and after the first 30 days, MRSA cases were more than twice as
likely to fail as those infected with MSSA, while after antibiotic treatment, MSSA cases
failed more than MRSA cases.46 In another study of 98 patients with PJIs caused by S.
aureus during 2000 to 2006, the treatment failure rate was higher, but not significant
(p=0.38), in infections caused by MRSA compared to those caused by MSSA, and the
treatment failure rates were 29.4% and 19.7 % in MRSA- and MSSA-infected patients,
respectively.47 Similarly, higher although not significant (p=0.242) recurrent infection rates
were found in MRSA infected patients compared to MSSA infected patients among 61 S.
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aureus infected hip and knee patients from 1998–2011.48 MRSA infected patients showed
significantly higher erythrocyte sedimentation rates, C-reactive proteins and neutrophil
percentages during their initial visits.48
Therefore, from the available case studies, we can conclude that orthopaedic implantassociated infections caused by microorganisms resistant to antibiotics likely have a less
optimal outcome compared to those caused by antibiotic susceptible microorganisms.

5. Challenges, opportunities, and obligations related to bacteria resistant
orthopaedic implant-associated infections

Author Manuscript

It is widely acknowledged that antibiotic resistance is one of the biggest threats facing
healthcare today.6 Due to antibiotic resistance and reduced availability of new antibiotics,
many routine surgical treatments such as hip and knee replacements are becoming
increasingly challenging and could be life threatening.49 There is little question that the
excessive and inappropriate use of antibiotics are the most important causes of antibiotic
resistance.50 This situation needs immediate action which must limit the spread of antibiotic
resistance, stimulate the development of new antibiotics and alternatives, and prolong the
effectiveness of current and new antibiotics. There is no doubt that both orthopaedic
surgeons and orthopaedic researchers may play important roles in such actions in reducing
the threat of antibiotic resistance, and the actions we take will only be sustained if based on
a sound understanding of the relative roles of many factors, particularly patients and
implants, microorganisms, orthopaedic surgeons and staff, and clinical settings (Fig. 3), in
the emergence, spread, and persistence of antibiotic resistance.
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Facing increasing challenges in antibiotic resistance, orthopaedic surgeons are presented
with multiple opportunities or obligations to alleviate the crisis. These include:
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•

Obligations for an honest and open discussion of orthopaedic implant infections.
It has been proposed that the current healthcare system in some regions of the
world (such as the U.S.) actually provides a financial incentive to attribute a
failed orthopaedic implant to anything but infection, even when infection is
involved. This incentive to attribute implant failures to causes other than
infection may stem from changes in healthcare reimbursement policy where
hospitals must now cover all costs (rather than insurance companies) if infection
occurs within a certain number of days post implantation. It is not until we have
an open and honest discussion about the prevalence of orthopaedic implant
infections that appropriate resources will be allocated to combat such infections.

•

Obligations to establish resistance surveillance, monitoring, and data-sharing,
which will assist orthopaedic surgeons in developing better evidence-based
databases for more appropriate antibiotic use.

•

Obligations to develop national and international principles and guidelines for
the use of antibiotics based on clinical evidence and apply them in practice,
combined with effective teamwork, communication, and accountability.
Antibiotics like rifampin has been commonly used in combination with other
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antibiotics to treat S. aureus infections, and has seemed to be promising in
treating orthopaedic implant-associated infections; however, data supporting this
practice are limited and more definitive data are lacking.51 Guidelines for
prophylaxis and treatment of orthopaedic infections have been established,52–54
and if implemented worldwide, they could have immense impact on healthcare
policy and practices. These principles and guidelines will enable orthopaedic
surgeons to be more effective in preventing infections and reducing the use of
antibiotics. Preventing patients from developing acute infections after
orthopaedic surgeries will eliminate the need for extended antibiotic use for
possible chronic or recurrent infections.

Author Manuscript
Author Manuscript

•

Obligations to explore personalized medicine. In current practice, the treatment
of patients for orthopaedic infections is completed sometimes without even
knowing bacteria antibiotic resistant profiles and is not based on a thorough
review of patient history.

•

Obligations to establish and follow stricter hygiene (especially hand hygiene)
measures, which will lead to a further reduction in the transmission of antibiotic
resistance or microorganisms. One of the most common vehicles for resistance
transmission is the human hand, which can become easily contaminated in
contact with the patient or the clinical settings near the patient.

•

Obligations to further promote practicing and advocating antimicrobial
stewardship – structured guidance and support for responsible selection and
utilization of antibiotics – orthopaedic surgeons may better train the next
generation of orthopaedic surgeons. – Obligations to broaden their coordination
with international efforts in reducing antibiotic resistance. Antibiotic resistance is
a global problem, and has been exacerbated by the ease of international travel
and trade, and increasing global population densities.

Orthopaedic researchers are also presented with tremendous opportunities in searching for
strategies to avoid or inhibit antibiotic resistance. Such opportunities include:
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•

Developing advanced diagnostic methods, which would need to be simple, quick,
accurate, and low cost, to detect and profile antibiotic resistance genes or
microorganisms. Diagnostic tests are crucial to the management of infectious
diseases and combatting the rise in antibiotic resistance,55 and the introduction of
rapid and accurate diagnostics tests into orthopaedic surgeons’ offices will likely
influence their prescribing of a more rational use of antibiotics. As an example,
differentiating between Gram-positive and Gram-negative bacteria would be
expected to significantly facilitate the appropriate use of antibiotics.

•

Searching for new antibiotic targets and antibiotics with multiple modes of
actions against bacteria, and rejuvenating or repurposing current and old
antibiotics. Antibiotics with multiple modes of antimicrobial action would help
reduce antibiotic resistance. Screening for new antibiotics from natural sources
could broaden the possibilities for treating infections. New antibiotics do not
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have to have equal effectiveness against Gram-positive and Gram-negative
resistant microorganisms.
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•

Developing advanced antibiotic cocktails that may have synergistic antimicrobial
effects or are less likely induce resistance. Scientific and clinical evidence should
be used for specific combinations of antibiotics rather than the ad hoc
combinations that are sometimes chosen by prescribers. Such cocktail
approaches (e.g., a fluoroquinolone plus a macrolide) have been applied with
success in the treatment of diseases like HIV infection.

•

Discovering non-antibiotic drugs and effective vaccines, bacteriophages, or
immunotherapeutic approaches. Multiple antibiotic alternatives have been
studied,56–59 and some drugs, which may not exhibit direct bacteriostatic or
bactericidal activities, may stimulate or recruit the host’s innate immune
system56,60 and they may be used in conjunction with antibiotics.61 Many of
these alternative strategies are promising but, unfortunately, are still in their early
development stages.

•

Expansion of research into non-biomolecule approaches to keep bacteria from
attaching to implant surfaces and thus allowing the immune system to clear such
microorganisms more easily. Specifically, research in the area of nanotechnology
has led to the generation of nanoscale surface features that can both decrease
bacteria attachment and increase osseointegration without the use of antibiotics
or biomolecules.62–65 Such approaches can provide a quick and effective FDA
approval process to reduce orthopaedic implant infections that do not involve
antibiotics.

•

Further examining the mechanisms of antibiotic resistance. Antibiotic resistance
has been in existence for a long time and new resistance mechanisms continue to
occur. A better mechanistic and structural understanding will allow researchers
to tackle the origin of resistance.

Along with the opportunities and obligations described above come the challenges facing
orthopaedic surgeons and researchers, among all parties involved, in dealing with increasing
antibiotic resistance:
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•

How to collaborate with pharmaceutical companies in the discovery and
development of new antibiotics or alternatives? The investment and interest of
pharmaceutical companies in the discovery and development of new antibiotics
is decreasing,2 since finding new antibiotics is challenging and the return on
investment is poor compared to other therapeutic areas (e.g., drugs for long-term
chronic diseases). Note that actions like the Generating Antibiotics Incentives
Now Act (GAIN Act) signed to law in 2012 are positive but may not be attractive
enough for pharmaceutical companies.

•

How to effectively eliminate antibiotic resistance transmission? It is important to
break the transmission chains of antibiotic resistance genes because, even if we
are able to make new antibiotics or alternative treatments, bacteria are likely to
develop resistance within short time periods.
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•

How to control antibiotic waste? Antibiotic waste should not simply be dumped
into the environment, which houses various microorganisms that have been
contributing to the emergence and spread of antibiotic resistance.

•

How to efficiently publicize scientific findings, either from laboratories or
bedside, and make them readily accessible and understood by the general public?
The public plays an important role in antibiotic resistance emergence and
spreading. However, a recent study found that the public was aware of the
contributions of antibiotic misuse and overuse to resistance, but many do not
consider antibiotic resistance to be an important health problem.66

•

Screening for resistance may come with issues. Screening all patients on
admission for various potential resistant microorganisms may not be costeffective at this point, while screening for only one microorganism while
ignoring others may seem unwise. Also, isolation of patients infected with
resistant microorganisms has been effective in reducing the spread of resistance
but it could be problematic with regard to children, for whom extended isolation
may pose unique challenges to families.

•

New antibiotic resistance mechanisms are emerging, and infections caused by
multidrug-resistant Gram-negative bacteria are increasingly seen and are
particularly difficult to treat. New antibiotics or alternative treatments will have
to tackle this challenge as well.

•

Antibiotic alternatives may reduce the use of antibiotics; however, the role of
non-antibiotic drugs in developing antibiotic resistance has not been examined
yet and is not clear.

•

The majority of research to date focuses on infections formed by a single species
of bacteria; however, most infections are polymicrobial (consisting of two or
more bacterial species)33–35,67 which is more difficult to treat.68 It is not clear
whether polymicrobial infections have higher antibiotic resistance compared to
monomicrobial infections and the role of each individual microorganism in
contributing to antibiotic resistance is also unknown.

•

Lack of funding nationally and globally; the U.S. has pledged a significant
increase in funding in research related to antibiotic resistance but, compared to
the magnitude of resistance, the funding is not sufficient and globally, we
continue to lag behind. Every month, it appears that a new microorganism threat
faces humans that we are ill-equipped to handle and we will continue to be illequipped to handle unless research moves ahead of such outbreaks.

In summary, in orthopaedic infections, antibiotic resistant microorganisms likely lead to less
than optimal clinical outcomes compared to those that are susceptible to antibiotics. The
increasing occurrence of antibiotic resistance has presented unique opportunities,
obligations, and challenges to orthopaedic researchers and surgeons.
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Fig. 1.

Timeline showing the time between the introduction of an antibacterial and the development
of clinically significant resistance. Reprinted with permission from 4.
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Fig. 2.

Author Manuscript

(A) Intrinsic mechanisms of resistance. The figure shows an overview of intrinsic resistance
mechanisms. The example shown is of β-lactam antibiotics targeting a penicillin-binding
protein (PBP). Antibiotic A can enter the cell via a membrane-spanning porin protein, reach
its target and inhibit peptidoglycan synthesis. Antibiotic B can also enter the cell via a porin,
but unlike Antibiotic A, it is efficiently removed by efflux. Antibiotic C cannot cross the
outer membrane and so is unable to access the target PBP. Reprinted by permission from
Macmillan Publishers Ltd: Nature Reviews Microbiology,14 copyright (2015). (B) The four
resistance acquisition pathways, the four main mechanisms of resistance, and the five main
targets for antibiotics. Reprinted with permission from 19.
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Fig. 3.

Major factors that contribute to the emergence, spread, and persistence of antibiotic
resistance in orthopaedic implant-associated infections.
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Table 1

Author Manuscript

Effects of antibiotic resistance. Reprinted from reference,7 Clinical Microbiology and Infection, 22, Friedman
ND, Temkin E, Carmeli Y. The negative impact of antibiotic resistance, 416–422. Copyright (2016), with
permission from Elsevier.
The effect

Examples

Morbidity and mortality

All-cause
Attributable to infection
Increased length of hospital stay
Increased length of mechanical ventilation
Increased need for intensive care and invasive devices
Excess surgery
Functional decline and need for post-acute care
Need for contact isolation

Author Manuscript

Loss of work
Increased resource utilization and cost

Hospital, intensive-care unit and post-acute care beds
Additional nursing care, support services, diagnostic tests and imaging
Additional use of isolation rooms and consumables (gloves, gowns)
Cost of targeted infection control programs including screening, isolation

Guideline alterations

Loss of narrow-spectrum antibiotic classes
Altered empiric therapy regimens
Use of agents with reduced efficacy
Use of agents with increased toxicity

Reduced hospital activity

Unit closures
Cancellation of surgery
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Table 2

Author Manuscript

Prevalence and antibiotic resistance in orthopaedic surgeries.

Author Manuscript

Infection

Microorganism

Antibiotic resistance profile

1131 Staphylococcal
strains isolated from
patients undergoing
revision of surgical
wounds and treatment of
infected prostheses

193 were identified as Staphylococci other
than S. aureus and S. epidermidis. S.
hominis, S. haemolyticus, S. capitis, S.
warneri, and S. cohnii were relatively
prevalent, being 4.2%, 3.7%, 2.7%, 2.6%,
and 1.6%, respectively.

These 193 species were often (e.g. 51–66%) resistant to
penicillin and had significantly different patterns of
resistance toward other antibiotics like ampicillin,
clindamycin, erythromycin, gentamicin, tobramycin, and
vancomycin.

32

Seven knee PJIs

Escherichia coli (E. coli) was isolated in six
cases and Klebsiella pneumoniae in one
case.

E. coli was resistant to ciprofloxacin but susceptible to
gentamicin and Klebsiella pneumoniae was resistant to
ciprofloxacin and gentamicin but susceptible to
cotrimoxazole.

33

4009 primary hip and knee
arthroplasties with an
overall infection rate of
0.87%

The most common infecting organisms
were coagulase-negative Staphylococci or
CNS (35%) and S. aureus (25%).

92% of the CNS strains were cefazolin-resistant and 9.1%
of the S. aureus strains were methicillin-resistant. Overall,
53% of the organisms was cefazolin-resistant.

34

~800 orthopaedic clinical
isolates from infections
associated with prosthetic
implants

34% were S. aureus, 32% S. epidermidis,
8% Pseudomonas, 5% Enterococcus, 2%
Escherichia, 2% Streptococcus, and 13%
other CNS.

~80% of both S. aureus and S. epidermidis were resistant
to cephalosporins (penicillin drugs) and ~40% had
methicillin/oxacillin resistance.

35

72 revision PJIs

S. aureus (36%) and CNS (35%) were the
most common infective organisms.

S. aureus and CNS were resistant to methicillin (20% vs.
72%) and gentamicin (4% vs. 40%).

36

12 patients undergoing
one-stage revision of
aseptic implant loosening
(had no clinical
manifestations of
infection)

All patients were positive for bacterial
growth. Staphylococci were the
overwhelming majority and CNS was
cultured from nine patients with eight S.
epidermidis isolates and one S. warneri.

Staphylococcal isolates were resistant to methicillin (8
isolates), macrolides, lincosamides, and group B
streptogramins (4), aminoglycosides (4), cotrimoxazole
(3), ciprofloxacin (3), fusidic acid (3), and rifampin (1).
Five out of ten were MDR.

37

19 patients who had
implant failure
accompanied with
ongoing PJIs

Staphylococci were the only
microorganisms. S. epidermidis and S.
aureus were cultured from 11 and four
patients, respectively, in addition to S.
warneri (2 isolates), S. lugdunensis (1), S.
simulans (1), and S. captitis (1).

These Staphylococci were resistant to methicillin (12
isolates), macrolides, lincosamides, and group B
streptogramins (6), aminoglycosides (5), cotrimoxazole
(4), ciprofloxacin (3), fusidic acid (2), and rifampin (3).
Seven Staphylococcal isolates were MDR.

37
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Table 3

Author Manuscript

Poorer clinical outcomes of orthopaedic patients infected by MRSA compared to those infected by MSSA.
Time

Patient

Outcome

1995–2004

43 patients with periprosthetic joint infections

Significantly longer hospital stay (15 vs. 10 days).
Significantly higher risk of treatment failure

40

1997–2001

70 patients with periprosthetic joint infections

Successfully treated only 48% and 18% of hip and knee replacements,
respectively, in MRSA infected patients compared to 81% and 89% in
MSSA infected cases

41

1998–2004

31 patients with delayed deep infection after
total knee arthroplasty

Significantly higher mean number of surgical procedures per patient.
Significantly lower proportion of patients with satisfactory outcomes

42

2000–2002

59 children with musculoskeletal infections

Significantly longer febrile days and hospital stays.

43

2004–2008

74 children with bone and joint infections

Significantly longer duration of febrile days, hospital stays, and
antibiotic treatment

44

2005–2011

30 vertebral osteomyelitis patients (16 cases
of MRSA and 14 MSSA)

Significantly higher rate of patients to undergo surgical procedure
within three months (56.3% vs. 14.3%)

45
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